Abstract
Dual inhibitors are drugs able to block both the COX and the 5-LOX metabolic pathways. The interest of developing such compounds is supported by a large number of pharmacological studies. Compared to COX or LOX pathways single inhibitors, dual inhibitors present at least two major advantages. First, dual inhibitors, by acting on the two major arachidonic acid metabolic pathways, possess a wide range of antiinflammatory activity. Secondly, dual inhibitors appear to be almost exempt from gastric toxicity, which is the most troublesome side effect of COX inhibitors. The mechanism of their gastric-sparing properties is not completely understood, although it has been demonstrated that leukotrienes significantly contribute to the gastric epithelial injury. Finally, both COX and LOX derivatives (prostanoids and leukotrienes, respectively) are involved in other diseases than inflammation such as cancer proliferation where the use of dual inhibitors could be an interesting approach.
Keywords: cox inhibitors, prostanoids, leukotrienes, eicosanoids, cyclooxygenase, peroxidase, meclofenamic acid, flufenamic acid, mefenamic acid, niflumic acid
Current Medicinal Chemistry
Title: New Trends in Dual 5-LOX / COX Inhibition
Volume: 9 Issue: 9
Author(s): Xavier de Leval, Fabien Julemont, Jacques Delarge, Bernard Pirotte and Jean-Michel Dogne
Affiliation:
Keywords: cox inhibitors, prostanoids, leukotrienes, eicosanoids, cyclooxygenase, peroxidase, meclofenamic acid, flufenamic acid, mefenamic acid, niflumic acid
Abstract: Dual inhibitors are drugs able to block both the COX and the 5-LOX metabolic pathways. The interest of developing such compounds is supported by a large number of pharmacological studies. Compared to COX or LOX pathways single inhibitors, dual inhibitors present at least two major advantages. First, dual inhibitors, by acting on the two major arachidonic acid metabolic pathways, possess a wide range of antiinflammatory activity. Secondly, dual inhibitors appear to be almost exempt from gastric toxicity, which is the most troublesome side effect of COX inhibitors. The mechanism of their gastric-sparing properties is not completely understood, although it has been demonstrated that leukotrienes significantly contribute to the gastric epithelial injury. Finally, both COX and LOX derivatives (prostanoids and leukotrienes, respectively) are involved in other diseases than inflammation such as cancer proliferation where the use of dual inhibitors could be an interesting approach.
Export Options
About this article
Cite this article as:
Leval de Xavier, Julemont Fabien, Delarge Jacques, Pirotte Bernard and Dogne Jean-Michel, New Trends in Dual 5-LOX / COX Inhibition, Current Medicinal Chemistry 2002; 9 (9) . https://dx.doi.org/10.2174/0929867024606713
DOI https://dx.doi.org/10.2174/0929867024606713 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of L-Glucose in Cancer Diagnosis: Results from In Vitro and In Vivo Studies
Current Medicinal Chemistry The Role of P2X Receptors in Bone Biology
Current Medicinal Chemistry Mechanism and Inhibition of Matrix Metalloproteinases
Current Medicinal Chemistry Nosocomial Infections and Antimicrobial Treatment in Coiled Patients with Aneurysmal Subarachnoid Hemorrhage
Current Drug Targets The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Anti-Cancer Agents in Medicinal Chemistry LW-AFC, A New Formula Derived from Liuwei Dihuang Decoction, Ameliorates Cognitive Deterioration and Modulates Neuroendocrine-Immune System in SAMP8 Mouse
Current Alzheimer Research Autism - A Comprehensive Array of Prominent Signs and Symptoms
Current Pharmaceutical Design Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Inhibitors of TACE and Caspase-1 As Anti-inflammatory Drugs
Current Medicinal Chemistry Current Breakthroughs in Structure-based Design of Synthetic and Natural Sourced Inhibitors Against Zika Viral Targets
Current Topics in Medicinal Chemistry HLAs in Autoimmune Diseases: Dependable Diagnostic Biomarkers?
Current Rheumatology Reviews Pharmacogenomics of Oral Antithrombotic Drugs
Current Pharmaceutical Design Liver X Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Potential Mechanism of N-acetylcysteine in Treating COVID-19
Current Pharmaceutical Biotechnology Moxifloxacin Hydrochloride-Loaded Eudragit® RL 100 and Kollidon® SR Based Nanoparticles: Formulation, In vitro Characterization and Cytotoxicity
Combinatorial Chemistry & High Throughput Screening HPLC-fluorescence Determination of EROD Activity in Wistar Rat Liver Microsomes Obtained by Two Different Extraction Procedures
Current Pharmaceutical Analysis Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Current Drug Safety Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection
Current Drug Metabolism Expression Profiling of Estrogen Responsive Genes Using Genomic and Proteomic Techniques for the Evaluation of Endocrine Disruptors
Current Pharmacogenomics GABAergic Agonists Modulate the Glutamate Release from Frontal Cortex Synaptosomes of Rats with Experimental Autoimmune Encephalomyelitis
Inflammation & Allergy - Drug Targets (Discontinued)